Medtronic Activa Medicare Coverage Decision Favored By Tech Assessment
This article was originally published in The Gray Sheet
Executive Summary
Clinical studies evaluating bilateral deep-brain stimulation (DBS) for treatment of Parkinson's disease support improved health outcomes associated with the procedure, a BlueCross BlueShield Association technology assessment suggests
You may also be interested in...
Medtronic Activa coverage
Review of Medicare coverage for deep brain stimulation (DBS) for Parkinson's disease is slated to go before Medicare Coverage Advisory Committee's Medical and Surgical Products Panel June 12, CMS reports March 8. The decision to put the issue before the panel likely will push what was most recently an April 5 deadline for a coverage decision into August. In February, CMS released a favorable BlueCross BlueShield Association technology assessment commissioned by the agency (1"The Gray Sheet" Feb. 11, 2002, p. 7)...
Medtronic Activa coverage
Review of Medicare coverage for deep brain stimulation (DBS) for Parkinson's disease is slated to go before Medicare Coverage Advisory Committee's Medical and Surgical Products Panel June 12, CMS reports March 8. The decision to put the issue before the panel likely will push what was most recently an April 5 deadline for a coverage decision into August. In February, CMS released a favorable BlueCross BlueShield Association technology assessment commissioned by the agency (1"The Gray Sheet" Feb. 11, 2002, p. 7)...
Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer
Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer